Zimbabwe has declined a significant American healthcare agreement valued at $367m (£272m) spanning five years because of Washington's request for sensitive biological samples.
The decision was revealed after a official document dated December was disclosed, which showed Head of State Emmerson Mnangagwa felt the agreement was "unbalanced".
An official representative has since stated that the United States was demanding access to health data for research and commercial gain but was unwilling to guarantee the benefits from future vaccines.
"We must now begin the difficult and regrettable task of winding down our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has called for continued dialogue to reach a deal acceptable to all parties so the nation's critical HIV programme can proceed.
Broader Context
Zimbabwe's decision follows a similar case in neighbouring Kenya, where a high court suspended a similar deal with the US after legal challenges were filed about the security of citizens' medical information.
After returning to office last year, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered aid for the American government, but Trump stated its spending was "wasteful" and his government was seeking government-to-government deals to boost openness and accountability.
According to reports, 16 nations in Africa have to date signed these new health pacts, constituting over $18.3bn of fresh investment.
Specifics of the Rejected Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration would have delivered immense benefits for Zimbabwean communities, particularly the 1.2 million currently on antiretroviral therapy via US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no equivalent guarantee of access to any scientific breakthroughs – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"In essence, our country would supply the raw materials for scientific discovery without any certainty that the resulting innovations would be available to our population should a future health crisis arise."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its push of one-on-one deals were disrupting structures previously set up through the global organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with future pandemics.
"This system is designed to ensure that when a nation provides its data, the benefits – such as medicines and cures – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," Mangwana stressed.
"We encourage continued discussions with our US partners on how future co-operation might be structured in a manner that respects the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but urged that negotiations must proceed since a large portion of the nation's HIV programmes were funded by international support.
"If technical issues exist, including those relating to data governance or implementation frameworks, these can frequently be resolved via detailed discussion and mutually agreed protections," it said.
The situation underscores the continuing challenges between receiving much-needed foreign assistance and protecting national sovereignty in an ever more data-driven world.